

Page 1 of 2  
CFF 10463867 Revision 02  
Only the Native File to be Used

K070279 pg 1 of 2

**510(k) Summary of Safety and Effectiveness**

**Submitter's  
Name/Contact  
Person**

Roberto F. Refeca  
Senior Regulatory Affairs Associate

MAR 14 2007

Cordis Neurovascular, Inc.  
14000 NW 57<sup>th</sup> Ct.  
Miami Lakes, FL 33014

Ph. 786 313 2850  
Fax. 786 313 6480  
rrefeca@crdus.jnj.com

**Trade Name /  
Common Name**

**The trade name/common name is :**  
HYPERTRANSIT<sup>™</sup> Infusion Catheter/Catheter, Continuous Flush

**Classification**

This is a Class II Device, per 870.1210 (KRA).

**Performance  
Standard**

The FDA under Section 514 of the Food, Drug and Cosmetic Act has not established performance standards for this device.

**Intended use**

The HYPERTRANSIT<sup>™</sup> Infusion Catheter is intended to be used as a mechanism for the infusion of various diagnostic and embolic agents in the coronary, neuro and peripheral vasculatures, for guidewire exchange/support, and for superselective angiography of the peripheral and coronary vessels. The device is also intended to be used for infusion of therapeutic agents in the coronary and peripheral vasculature. All agents must be used in accordance with manufacturer's instructions for use.

**Device  
Description**

The Cordis Neurovascular, Inc. HYPERTRANSIT<sup>™</sup> Infusion Catheter is a variable stiffness, single lumen catheter designed to access small, tortuous vasculature. Each configuration has a hydrophilic coating to provide lubricity for navigation of vessels. The inner lumen is lined with PTFE to facilitate movement of guidewires and other devices. The catheter body is radiopaque to aid visualization under fluoroscopy, and the distal tip is distinguished by a radiopaque marker. Select configurations are available with pre-shaped tips.

Page 2 of 2

CFF 10463867 Revision 02

Only the Native File to be Used

**Predicate Devices** The predicate devices are listed in the table below:

Device	Company	Product Code	510(k) Number	Predicate for: (if multiple predicates)
<b>HYPERTRANSIT™</b> Infusion Catheter	Cordis Neurovascular, Inc.	KRA	K043538	Intended Use Sterilization Dimensions Performance Packaging Manufacturing

**Summary of Studies**

The following in-vitro testing was conducted to support substantial equivalence to the predicate device, addressing the design changes made to improve kink resistance at the distal end of the strain relief.

<b>PERFORMANCE &amp; DESIGN VALIDATION TESTING</b>
Microcatheter Visual Standards for Kinks
Microcatheter Inspection
Dynamic Burst
Static Burst
Joint Pull Test

**Summary of Substantial Equivalence**

The proposed **HYPERTRANSIT™** Infusion Catheter is similar in its basic design, construction, indication for use, and performance characteristics to the predicate **HYPERTRANSIT™** Infusion Catheter.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAR 14 2007

Mr. Roberto F. Refeca  
Sr. Regulatory Affairs Associate  
Cordis Neurovascular, INC.  
14000 N.W. 57<sup>th</sup> Court  
Miami Lakes, FL 33014

Re: K070279/S001  
Trade/Device Name: HYPERTRANSIT™ Infusion Catheter  
Regulation Number: 21 CFR 870.1210  
Regulation Name: Catheter, Continuous Flush  
Regulatory Class: Class II  
Product Code: KRA  
Dated: February 14, 2007  
Received: February 16, 2007

Dear Mr. Refeca:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can

Page 2 – Mr. Roberto F. Refeca


be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Bram D. Zuckerman', with a long horizontal flourish extending to the right.

Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K070279

Device Name: **HYPERTRANSIT™** Infusion Catheter

**Indications For Use:** The HYPERTRANSIT™ Infusion Catheter is intended to be used as a mechanism for the infusion of various diagnostic and embolic agents in the coronary, neuro and peripheral vasculatures, for guidewire exchange/support, and for superselective angiography of the peripheral and coronary vessels. The device is also intended to be used for infusion of therapeutic agents in the coronary and peripheral vasculature.


All agents must be used in accordance with manufacturer's instructions for use.

Prescription Use   X   AND/OR Over-The-Counter Use         
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
Vision Sign-Off  
Division of Cardiovascular Devices  
510(k) Number K070279